基本信息
views: 78
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Yufei Xu is a passionate drug hunter with extensive experience in small molecule and biologics drug discovery as well as cell therapy
on cancer immunology, oncology, cardiovascular and metabolic
diseases in both large pharma and small biotech company. Dr.
Xu has led and progressed several drug discovery projects from
target discovery & validation to lead optimization and development.
He holds strong expertise in new target discovery and validation,
molecular glue discovery, targeted protein degradation, CART
cell therapies, drug MoA study, functional siRNA/shRNA/CRISPR
genomic library screen, high throughput biochemical and cellular
assay development, PD biomarker discovery, functional cellular
assay development, in vivo PK/PD and efficacy model development
and study design and deep understanding fundamental biology
by single cell RNAseq, bulk RNAseq and epigenome profiling. Dr.
Xu has published numerous peer-reviewed papers in high impact
journals, such as 2 first author papers in Cell (cited ~1000 times),
1 first author paper in Molecular Cell (cited >600 times), and is
inventors for 4 patents
Research Interests
Papers共 89 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EBioMedicine (2024): 104940
Cited0Views0Bibtex
0
0
JOURNAL OF GUIDANCE CONTROL AND DYNAMICSno. 4 (2024): 770-776
Niu Li,Yufei Xu,Hongzhu Chen, Jingqi Lin,Lama Alabdi,Mir Reza Bekheirnia,Guoqiang Li, Yoel Go,Nasim Bekheirnia,Eissa Faqeih,Lina Chen,Guoying Chang,
EBIOMEDICINE (2024): 104940-104940
Advances in Guidance, Navigation and Controlpp.1933-1943, (2023)
Cell reportsno. 6 (2022): 111600-111600
PEDIATRIC NEUROLOGY (2022): 30-41
wf(2022)
Load More
Author Statistics
#Papers: 17
#Citation: 192
H-Index: 5
G-Index: 13
Sociability: 4
Diversity: 0
Activity: 0
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn